Clinical Trial Update: Ascending Dose Tolerability/Safety of SLV308 for the Treatment of Parkinson's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial updating ascending-dose tolerability and safety data for SLV308 in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SLV308

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED